Corbus Pharmaceuticals Holding

Corbus Pharmaceuticals Holdings Inc. is an American clinical-stage pharmaceutical company with a specialisation in immunology. Operating globally, the firm is primarily focused on the discovery, development, and commercialisation of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Diseases in this category include sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The firm was founded in 2009 and has its corporate headquarters in Norwood, Massachusetts. The firm’s specific therapeutic focus areas are immuno-oncology, metabolism, inflammation, and fibrosis. The Corbus Pharmaceuticals team is engaged in the development of a diverse pipeline of drug candidates, including small molecule therapies as well as biologics. The company's lead product candidate, Lenabasum, is a novel synthetic oral cannabinoid receptor type 2 (CB2) agonist, which is used to treat chronic inflammation, limit fibrosis, and support tissue repair. Corbus Pharmaceuticals is also developing a pipeline of drug candidates from more than 600 novel compounds targeting the endocannabinoid system. Other products in the company’s pipeline are at various clinical phases and target solid tumours, fibrosis, and metabolism disorders. The firm is listed on the NASDAQ, where it trades under the stock ticker CRBP. Track changes in the Corbus Pharmaceuticals share price when you add CRBP stock to your eToro watchlist.